Probiotics and Antimicrobial Proteins

, Volume 11, Issue 1, pp 158–164 | Cite as

Prevention of Renal Scarring in Acute Pyelonephritis by Probiotic Therapy: an Experimental Study

  • Nastaran Sabetkish
  • Shabnam Sabetkish
  • Mohammad Javad Mohseni
  • Abdol-Mohammad KajbafzadehEmail author


We evaluated the protective effects of probiotic administration as a prophylaxis treatment and immediately after fever onset in increasing the immune response and decreasing the renal scarring in a rat model of acute pyelonephritis. Twenty-four rats were apportioned to three groups. In GI (n = 8), the rats were injected with direct inoculation of Escherichia coli into the right kidney. In GII (n = 8), the rats received a probiotic regimen 1 month before E. coli injection and the probiotic regimen was continued for the next 2 months. In GIII (n = 8), the probiotic regimen was started just after E. coli injection and was continued for 2 months. Technetium-99m-DMSA renal scan, histopathological evaluations, concentrations of CA19-9, IgA, blood urea nitrogen (BUN), and creatinine were assessed 1 and 2 months post-injection. It took an average of 4.2 ± 1.1 h between the injection and onset of fever in GI and GII. In GIII, this period was longer (7.5 ± 1.4). Probiotic administration resulted in reduction of interstitial fibrosis and tubular and glomerular atrophy in GII in all follow-ups. Technetium-99m-DMSA renal scan showed that the right kidney reached near the normal cortical integrity (47%) in GII compared to GI (32%) after 2 months of injection. However, the renal integrity did not improve significantly in GIII (41%). In GII, CA19-9 was lower (p < 0.05), while the levels of serum and fecal IgA were higher (p < 0.05). Administration of the probiotic regimen in the rat model may decrease renal damage in pyelonephritis. In spite of better results in the prophylactic group compared to the treatment group, no strong evidence was found to prove the advantage of its prophylactic application over the treatment administration.


Acute pyelonephritis Fever Probiotics 



Acute pyelonephritis


Urinary tract infection

E. coli

Escherichia coli


Immunoglobulin A


Blood urea nitrogen



The authors acknowledge Miss Shahnaz Halimi of the Department of Microbiology, School of Medicine, Tehran University of Medical Sciences for bacterial culture. The authors thank the authorities in charge of R&D department of Iran Dairy Industries Co. (Pegah).

Funding Information

The authors would like to thank Tehran University of Medical Sciences for funding this study (Grant Number 29548).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethical Approval

The local ethics committee approved the experimental protocol. The principles of laboratory animal care (NIH publication no. 85–23, revised 1985) were respected for animal treatment.


  1. 1.
    Wassner S, Baum M (1999) Physiology and management. Pediatric Nephrology Lippincott Williams Wilkins, Baltimore, pp 1155–1182Google Scholar
  2. 2.
    LeBrun M, Grenier L, Gourde P, Bergeron MG, Labrecque G, Beauchamp D (1999) Effectiveness and toxicity of gentamicin in an experimental model of pyelonephritis: effect of the time of administration. Antimicrob Agents Chemother 43(5):1020–1026CrossRefGoogle Scholar
  3. 3.
    Koch VH, Zuccolotto SM (2003) Urinary tract infection: a search for evidence. J Pediatr 79(Suppl 1):S97–106. CrossRefGoogle Scholar
  4. 4.
    Tekgül S (2015) A snapshot of the guidelines on vesicoureteral reflux in children. Eur Urol Suppl 14(1):9–11. CrossRefGoogle Scholar
  5. 5.
    Celik S, Gorur S, Aslantas O, Erdogan S, Ocak S, Hakverdi S (2007) Caffeic acid phenethyl ester suppresses oxidative stress in Escherichia coli-induced pyelonephritis in rats. Mol Cell Biochem 297(1–2):131–138. CrossRefGoogle Scholar
  6. 6.
    Kaur A, Garg U, Sethi A, Gorowara S, Sharma S, Ganguly N (1988) Effect of various oxygen free radical scavengers in preventing tissue injury caused by Escherichia coli in pyelonephritic mice. Biochem Int 16(6):1083–1093Google Scholar
  7. 7.
    Sadeghi Z, Kajbafzadeh AM, Tajik P, Monajemzadeh M, Payabvash S, Elmi A (2008) Vitamin E administration at the onset of fever prevents renal scarring in acute pyelonephritis. Pediatr Nephrol 23(9):1503–1510. CrossRefGoogle Scholar
  8. 8.
    Reid G, Chan RC, Bruce AW, Costerton JW (1985) Prevention of urinary tract infection in rats with an indigenous Lactobacillus casei strain. Infect Immun 49(2):320–324Google Scholar
  9. 9.
    Cadieux PA, Burton J, Devillard E, Reid G (2009) Lactobacillus by-products inhibit the growth and virulence of uropathogenic Escherichia coli. J Physiol Pharmacol 60 Suppl 6(Suppl 6):13–18Google Scholar
  10. 10.
    Kaye D (1971) The effect of water diuresis on spread of bacteria through the urinary tract. J Infect Dis 124(3):297–305. CrossRefGoogle Scholar
  11. 11.
    Rushton HG (1997) The evaluation of acute pyelonephritis and renal scarring with technetium 99m-dimercaptosuccinic acid renal scintigraphy: evolving concepts and future directions. Pediatr Nephrol 11(1):108–120. CrossRefGoogle Scholar
  12. 12.
    Chen SM, Mukoyama T, Sato N, Yamagata S, Arai Y, Satoh N, Ueda S (2002) Induction of nephrotoxic serum nephritis in inbred mice and suppressive effect of colchicine on the development of this nephritis. Pharmacol Res 45(4):319–324. CrossRefGoogle Scholar
  13. 13.
    Katouli M (2010) Population structure of gut Escherichia coli and its role in development of extra-intestinal infections. Iran J Microbiol 2(2):59–72Google Scholar
  14. 14.
    Montini G, Tullus K, Hewitt I (2011) Febrile urinary tract infections in children. N Engl J Med 365(3):239–250. CrossRefGoogle Scholar
  15. 15.
    Amdekar S, Singh V, Singh DD (2011) Probiotic therapy: immunomodulating approach toward urinary tract infection. Curr Microbiol 63(5):484–490. CrossRefGoogle Scholar
  16. 16.
    Serlachius E, Sundelin B, Eklof AC, Jahnke M, Laestadius A, Aperia A (1997) Pyelonephritis provokes growth retardation and apoptosis in infant rat renal cortex. Kidney Int 51(6):1855–1862. CrossRefGoogle Scholar
  17. 17.
    Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, Akira S, Takeda K, Lee J, Takabayashi K, Raz E (2004) Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126(2):520–528. CrossRefGoogle Scholar
  18. 18.
    Hopkin M (2004) Probiotic bacteria health boon. Nature 432:427CrossRefGoogle Scholar
  19. 19.
    Hsieh MH, Versalovic J (2008) The human microbiome and probiotics: implications for pediatrics. Curr Probl Pediatr Adolesc Health Care 38(10):309–327. CrossRefGoogle Scholar
  20. 20.
    Asahara T, Nomoto K, Watanuki M, Yokokura T (2001) Antimicrobial activity of intraurethrally administered probiotic Lactobacillus casei in a murine model of Escherichia coli urinary tract infection. Antimicrob Agents Chemother 45(6):1751–1760. CrossRefGoogle Scholar
  21. 21.
    Uehara S, Monden K, Nomoto K, Seno Y, Kariyama R, Kumon H (2006) A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. Int J Antimicrob Agents 28:30–34. CrossRefGoogle Scholar
  22. 22.
    Kontiokari T, Laitinen J, Jarvi L, Pokka T, Sundqvist K, Uhari M (2003) Dietary factors protecting women from urinary tract infection. Am J Clin Nutr 77(3):600–604CrossRefGoogle Scholar
  23. 23.
    Lee SJ, Shim YH, Cho SJ, Lee JW (2007) Probiotics prophylaxis in children with persistent primary vesicoureteral reflux. Pediatr Nephrol 22(9):1315–1320. CrossRefGoogle Scholar
  24. 24.
    Mohseni MJ, Aryan Z, Emamzadeh-Fard S, Paydary K, Mofid V, Joudaki H, Kajbafzadeh AM (2013) Combination of probiotics and antibiotics in the prevention of recurrent urinary tract infection in children. Iran J Pediatr 23(4):430–438Google Scholar
  25. 25.
    Grin PM, Kowalewska PM, Alhazzan W, Fox-Robichaud AE (2013) Lactobacillus for preventing recurrent urinary tract infections in women: meta-analysis. Can J Urol 20(1):6607–6614Google Scholar
  26. 26.
    Schwenger EM, Tejani AM, Loewen PS (2015) Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev 12:CD008772. Google Scholar
  27. 27.
    Bedi M, Gandhi M, Jacob G, Lekha V, Venugopal A, Ramesh H (2009) CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit? Indian J Gastroenterol 28(1):24–27. CrossRefGoogle Scholar
  28. 28.
    Aybek H, Aybek Z, Sinik Z, Demir S, Sancak B, Tuncay L (2006) Elevation of serum and urinary carbohydrate antigen 19-9 in benign hydronephrosis. Int J Urol 13(11):1380–1384. CrossRefGoogle Scholar
  29. 29.
    Kajbafzadeh AM, Elmi A, Talab SS, Emami H, Esfahani SA, Saeedi P (2010) Urinary and serum carbohydrate antigen 19-9 as a biomarker in ureteropelvic junction obstruction in children. J Urol 183(6):2353–2358. CrossRefGoogle Scholar
  30. 30.
    Majd M, Rushton HG, Jantausch B, Wiedermann BL (1991) Relationship among vesicoureteral reflux, P-fimbriated Escherichia coli, and acute pyelonephritis in children with febrile urinary tract infection. J Pediatr 119(4):578–585. CrossRefGoogle Scholar
  31. 31.
    Linné T, Fituri O, Escobar-Billing R, Karlsson A, Wikstad I, Aperia A, Tullus K (1994) Functional parameters and99mtechnetium-dimercaptosuccinic acid scan in acute pyelonephritis. Pediatr Nephrol 8(6):694–699. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  • Nastaran Sabetkish
    • 1
  • Shabnam Sabetkish
    • 1
  • Mohammad Javad Mohseni
    • 1
  • Abdol-Mohammad Kajbafzadeh
    • 1
    Email author
  1. 1.Pediatric Urology and Regenerative Medicine Research Center, Section of Tissue Engineering and Stem Cells Therapy, Children’s Hospital Medical CenterTehran University of Medical SciencesTehranIran

Personalised recommendations